MNKD - NASDAQ
MannKind Corporation
$3.49
+1.7%MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
At a Glance
Live SnapshotMannKind Corporation Management Team
Dr. Michael E. Castagna Pharm.D.
Chief Executive Officer & Director
Compensation
$1,560,678
Mr. Christopher B. Prentiss M.B.A.
Chief Financial Officer
Compensation
$824,525
Dr. Stuart A. Tross Ph.D.
Executive Vice President of Human Resources
Compensation
$739,453
Ms. Lauren M. Sabella
Executive Vice President of Operations
Compensation
$768,906
Dr. Burkhard Blank M.D.
Executive Vice President of Research & Development and Chief Medical Officer
Compensation
$756,839
Mr. Sanjay Singh M.B.A.
Executive Vice President of Technical Operations
Compensation
$364,529
Dr. David B. Thomson J.D., Ph.D.
Executive Vice President, General Counsel & Secretary
Compensation
$858,438
Dr. Kevin Kaiserman M.D.
Senior Vice President & Therapeutic Area Head of Endocrine Diseases
Mr. John F. Bedard
Senior Vice President of Worldwide Regulatory Affairs
Ms. Rosabel Realica Alinaya CPA
Vice President of Investor Relations & Treasury
Compensation
$402,256
MannKind Corporation Insider Positioning
During the last 12 months, insiders have purchased $309K and sold $4.25M worth of MNKD shares, resulting in $3.94M of net selling activity.
3 Months
100.0K
259.00K
20.0K
65.71K
+193K
+$193K
3-6 Months
0
0.00
134.1K
820.89K
-821K
-$821K
6-9 Months
0
0.00
338.5K
1.87M
-1.9M
-$1.87M
9-12 Months
12.8K
50.00K
384.4K
1.50M
-1.4M
-$1.45M
Top Buyers
Castagna Michael
Director, Officer: Chief Executive Officer
$259K
Tross Stuart A
Officer: Chief People & Workpl Officer
$50K
Top Sellers
Castagna Michael
Director, Officer: Chief Executive Officer
$1.55M
Thomson David
Officer: Evp Genl Counsel & Secretary
$979K
Binder Steven B.
Director
$684K
Tross Stuart A
Officer: Chief People & Workpl Officer
$657K
Singh Sanjay R
Officer: Evp Technical Operations
$249K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $3.94M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider sellers vs. 2 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
MNKD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 07, 2026 | April 07, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 01, 2025 | May 14, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 05, 2024 | May 15, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 10, 2023 | April 10, 2023 | ||
DEF 14A DEF 14A 2022 N/A | March 30, 2022 | May 10, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 07, 2021 | May 20, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 10, 2020 | May 21, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 28, 2019 | May 14, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 29, 2018 | May 16, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | November 17, 2017 | December 13, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.